Literature DB >> 20191492

Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.

Angelo Ravelli1, Lucia Trail, Cristina Ferrari, Nicolino Ruperto, Angela Pistorio, Clarissa Pilkington, Susan Maillard, Sheila K Oliveira, Flavio Sztajnbok, Ruben Cuttica, Matilde Beltramelli, Fabrizia Corona, Maria Martha Katsicas, Ricardo Russo, Virginia Ferriani, Ruben Burgos-Vargas, Silvia Magni-Manzoni, Eunice Solis-Valleoj, Marcia Bandeira, Francesco Zulian, Vicente Baca, Elisabetta Cortis, Fernanda Falcini, Maria Alessio, Maria Giannina Alpigiani, Valeria Gerloni, Claudia Saad-Magalhaes, Rosanna Podda, Clovis A Silva, Loredana Lepore, Enrico Felici, Federica Rossi, Elena Sala, Alberto Martini.   

Abstract

OBJECTIVE: To investigate the long-term outcome and prognostic factors of juvenile dermatomyositis (DM) through a multinational, multicenter study.
METHODS: Patients consisted of inception cohorts seen between 1980 and 2004 in 27 centers in Europe and Latin America. Predictor variables were sex, continent, ethnicity, onset year, onset age, onset type, onset manifestations, course type, disease duration, and active disease duration. Outcomes were muscle strength/endurance, continued disease activity, cumulative damage, muscle damage, cutaneous damage, calcinosis, lipodystrophy, physical function, and health-related quality of life (HRQOL).
RESULTS: A total of 490 patients with a mean disease duration of 7.7 years were included. At the cross-sectional visit, 41.2-52.8% of patients, depending on the instrument used, had reduced muscle strength/endurance, but less than 10% had severe impairment. Persistently active disease was recorded in 41.2-60.5% of the patients, depending on the activity measure used. Sixty-nine percent of the patients had cumulative damage. The frequency of calcinosis and lipodystrophy was 23.6% and 9.7%, respectively. A total of 40.7% of the patients had decreased functional ability, but only 6.5% had major impairment. Only a small fraction had decreased HRQOL. A chronic course, either polycyclic or continuous, consistently predicted a poorer outcome. Mortality rate was 3.1%.
CONCLUSION: This study confirms the marked improvement in functional outcome of juvenile DM when compared with earlier literature. However, many patients had continued disease activity and cumulative damage at followup. A chronic course was the strongest predictor of poor prognosis. These findings highlight the need for treatment strategies that enable a better control of disease activity over time and the reduction of nonreversible damage.

Entities:  

Mesh:

Year:  2010        PMID: 20191492     DOI: 10.1002/acr.20015

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  63 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 2.  Taxonomy for systemic lupus erythematosus with onset before adulthood.

Authors:  Clovis A Silva; Tadej Avcin; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

3.  Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?

Authors:  Lisa G Rider; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2010-09

4.  Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Authors:  G Esther A Habers; Adam M Huber; Gulnara Mamyrova; Ira N Targoff; Terrance P O'Hanlon; Sharon Adams; Janardan P Pandey; Chantal Boonacker; Marco van Brussel; Frederick W Miller; Annet van Royen-Kerkhof; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 5.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 6.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 7.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 8.  Sex Differences in Pediatric Rheumatology.

Authors:  Marco Cattalini; Martina Soliani; Maria Costanza Caparello; Rolando Cimaz
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

9.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies.

Authors:  Neil Martin; Petra Krol; Sally Smith; Kevin Murray; Clarissa A Pilkington; Joyce E Davidson; Lucy R Wedderburn
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

10.  Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Authors:  Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.